|
1
|
Rui R, Zhou L and He S: Cancer
immunotherapies: advances and bottlenecks. Front Immunol.
14:12124762023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hegde UP and Mukherji B: Current status of
chimeric antigen receptor engineered T cell-based and immune
checkpoint blockade-based cancer immunotherapies. Cancer Immunol
Immunother. 66:1113–1121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Johnson DB, Nebhan CA, Moslehi JJ and
Balko JM: Immune-checkpoint inhibitors: Long-term implications of
toxicity. Nat Rev Clin Oncol. 19:254–267. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tang S, Qin C, Hu H, Liu T, He Y, Guo H,
Yan H, Zhang J, Tang S and Zhou H: Immune checkpoint inhibitors in
non-small cell lung cancer: Progress, challenges, and prospects.
Cells. 11:3202022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang X, Zhu L, Zhang H, Chen S and Xiao
Y: CAR-T cell therapy in hematological malignancies: Current
opportunities and challenges. Front Immunol. 13:9271532022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sharma P, Hu-Lieskovan S, Wargo JA and
Ribas A: Primary, adaptive, and acquired resistance to cancer
immunotherapy. Cell. 168:707–723. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wherry EJ and Kurachi M: Molecular and
cellular insights into T cell exhaustion. Nat Rev Immunol.
15:486–499. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Binnewies M, Roberts EW, Kersten K, Chan
V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI,
Ostrand-Rosenberg S, Hedrick CC, et al: Understanding the tumor
immune microenvironment (TIME) for effective therapy. Nat Med.
24:541–550. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Soares H, Henriques R, Sachse M,
Ventimiglia L, Alonso MA, Zimmer C, Thoulouze MI and Alcover A:
Regulated vesicle fusion generates signaling nanoterritories that
control T cell activation at the immunological synapse. J Exp Med.
210:2415–2433. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Joshi RN, Stadler C, Lehmann R, Lehtiö J,
Tegnér J, Schmidt A and Vesterlund M: TcellSubC: An atlas of the
subcellular proteome of human T cells. Front Immunol. 10:27082019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou B, Hao Q, Liang Y and Kong E: Protein
palmitoylation in cancer: Molecular functions and therapeutic
potential. Mol Oncol. 17:3–26. 2023. View Article : Google Scholar :
|
|
12
|
Zmuda F and Chamberlain LH: Regulatory
effects of post-translational modifications on zDHHC
S-acyltransferases. J Biol Chem. 295:14640–14652. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mitchell DA, Vasudevan A, Linder ME and
Deschenes RJ: Protein palmitoylation by a family of DHHC protein
S-acyltransferases. J Lipid Res. 47:1118–1127. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang MM and Hang HC: Protein
S-palmitoylation in cellular differentiation. Biochem Soc Trans.
45:275–285. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stix R, Lee CJ, Faraldo-Gómez JD and
Banerjee A: Structure and mechanism of DHHC protein
acyltransferases. J Mol Biol. 432:4983–4998. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu T, Hou D, Zhao J, Lu X, Greentree WK,
Zhao Q, Yang M, Conde DG, Linder ME and Lin H: NLRP3 Cys126
palmitoylation by ZDHHC7 promotes inflammasome activation. Cell
Rep. 43:1140702024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Salaun C, Greaves J and Chamberlain LH:
The intracellular dynamic of protein palmitoylation. J Cell Biol.
191:1229–1238. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li H, Yuan Q, Wang S, Yu T and Qi X: Role
of S-palmitoylation in digestive system diseases. Cell Death
Discov. 11:3312025. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cai J, Cui J and Wang L: S-palmitoylation
regulates innate immune signaling pathways: molecular mechanisms
and targeted therapies. Eur J Immunol. 53:e23504762023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vartak N, Papke B, Grecco HE, Rossmannek
L, Waldmann H, Hedberg C and Bastiaens PI: The autodepalmitoylating
activity of APT maintains the spatial organization of palmitoylated
membrane proteins. Biophys J. 106:93–105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Han M, Lv Y, Chen Y, Li Z, Tian J, Zhou H,
Wang Y, Su W and Zhong J: Advances in targeting protein
S-palmitoylation in tumor immunity and therapy. Front Oncol.
15:15476362025. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Y, Li Y and Wu L: Protein
S-palmitoylation modification: Implications in tumor and tumor
immune microenvironment. Front Immunol. 15:13374782024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang Y, Zhang E, Mao X, Liu G and Pan Y:
Targeting palmitoylation: A novel frontier in cancer biology and
immunotherapy. Biochim Biophys Acta Rev Cancer. 1881:1895092026.
View Article : Google Scholar
|
|
24
|
Zhang Y, Fan S, He L and Li L: The
ZDHHC13/ZDHHC17 subfamily: From biological functions to therapeutic
targets of diseases. Pharmacol Res. 209:1074182024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nederstigt AE, Sardana S and Baggelaar MP:
Deciphering protein long-chain S-acylation using mass spectrometry
proteomics strategies. RSC Chem Biol. 6:1532–1545. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liao D, Huang Y, Liu D, Zhang H, Shi X, Li
X and Luo P: The role of s-palmitoylation in neurological diseases:
Implication for zDHHC family. Front Pharmacol. 14:13428302024.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yuan Y, Li P, Li J, Zhao Q, Chang Y and He
X: Protein lipidation in health and disease: Molecular basis,
physiological function and pathological implication. Signal
Transduct Target Ther. 9:602024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu Z, Xiao M, Mo Y, Wang H, Han Y, Zhao
X, Yang X, Liu Z and Xu B: Emerging roles of protein palmitoylation
and its modifying enzymes in cancer cell signal transduction and
cancer therapy. Int J Biol Sci. 18:3447–3457. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hao S, Mei Y, Chen S, Liu J, Zhang Y, Zhu
Z and Zuo K: Potential therapeutic target in oncology: Protein
palmitoylation (Review). Oncol Rep. 54:1172025. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qu M, Zhou X, Wang X and Li H:
Lipid-induced S-palmitoylation as a vital regulator of cell
signaling and disease development. Int J Biol Sci. 17:4223–4237.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Elliot Murphy R and Banerjee A: In vitro
reconstitution of substrate S-acylation by the zDHHC family of
protein acyltransferases. Open Biol. 12:2103902022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Malgapo MIP and Linder ME: Substrate
recruitment by zDHHC protein acyltransferases. Open Biol.
11:2100262021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Adachi N, Hess DT, McLaughlin P and
Stamler JS: S-Palmitoylation of a novel site in the β2-Adrenergic
receptor associated with a novel intracellular itinerary. J Biol
Chem. 291:20232–20246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Abrami L, Dallavilla T, Sandoz PA, Demir
M, Kunz B, Savoglidis G, Hatzimanikatis V and van der Goot FG:
Identification and dynamics of the human ZDHHC16-ZDHHC6
palmitoylation cascade. Elife. 6:e278262017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tomatis VM, Trenchi A, Gomez GA and
Daniotti JL: Acyl-protein thioesterase 2 catalyzes the deacylation
of peripheral membrane-associated GAP-43. PLoS One. 5:e150452010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sobocińska J, Roszczenko-Jasińska P,
Ciesielska A and Kwiatkowska K: Protein palmitoylation and its role
in bacterial and viral infections. Front Immunol. 8:20032018.
View Article : Google Scholar
|
|
37
|
Roth AF, Wan J, Bailey AO, Sun B, Kuchar
JA, Green WN, Phinney BS, Yates JR III and Davis NG: Global
analysis of protein palmitoylation in yeast. Cell. 125:1003–1013.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ma L, Zhang L, Liao Z, Xiu C, Luo X, Luo
N, Zhang L, He G and Chen J: Pharmacological inhibition of protein
S-palmitoylation suppresses osteoclastogenesis and ameliorates
ovariectomy-induced bone loss. J Orthop Translat. 42:1–14. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Edmonds MJ, Geary B, Doherty MK and Morgan
A: Analysis of the brain palmitoyl-proteome using both acyl-biotin
exchange and acyl-resin-assisted capture methods. Sci Rep.
7:32992017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zheng S, Lin J, Pang Z, Zhang H, Wang Y,
Ma L, Zhang H, Zhang X, Chen M, Zhang X, et al: Aberrant
cholesterol metabolism and Wnt/β-Catenin signaling coalesce via
Frizzled5 in supporting cancer growth. Adv Sci (Weinh).
9:e22007502022. View Article : Google Scholar
|
|
41
|
Ulengin-Talkish I, Parson MAH, Jenkins ML,
Roy J, Shih AZL, St-Denis N, Gulyas G, Balla T, Gingras AC, Várnai
P, et al: Palmitoylation targets the calcineurin phosphatase to the
phosphatidylinositol 4-kinase complex at the plasma membrane. Nat
Commun. 12:60642021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li X, Shen L, Xu Z, Liu W, Li A and Xu J:
Protein palmitoylation modification during viral infection and
detection methods of palmitoylated proteins. Front Cell Infect
Microbiol. 12:8215962022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Martin BR, Wang C, Adibekian A, Tully SE
and Cravatt BF: Global profiling of dynamic protein palmitoylation.
Nat Methods. 9:84–89. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sanders SS, Martin DD, Butland SL,
Lavallée-Adam M, Calzolari D, Kay C, Yates JR III and Hayden MR:
Curation of the mammalian palmitoylome indicates a pivotal role for
palmitoylation in diseases and disorders of the nervous system and
cancers. PLoS Comput Biol. 11:e10044052015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shah K, Al-Haidari A, Sun J and Kazi JU: T
cell receptor (TCR) signaling in health and disease. Signal
Transduct Target Ther. 6:4122021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Qin Z and Xu T: Deciphering the
deterministic role of TCR signaling in T cell fate determination.
Front Immunol. 16:15622482025. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mariuzza RA, Agnihotri P and Orban J: The
structural basis of T-cell receptor (TCR) activation: An enduring
enigma. J Biol Chem. 295:914–925. 2020. View Article : Google Scholar :
|
|
48
|
Brazin KN, Mallis RJ, Li C, Keskin DB,
Arthanari H, Gao Y, Wu SL, Karger BL, Wagner G and Reinherz EL:
Constitutively oxidized CXXC motifs within the CD3 heterodimeric
ectodomains of the T cell receptor complex enforce the conformation
of juxtaposed segments. J Biol Chem. 289:18880–18892. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kuhns MS and Davis MM: TCR signaling
emerges from the sum of many parts. Front Immunol. 3:1592012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xu C, Gagnon E, Call ME, Schnell JR,
Schwieters CD, Carman CV, Chou JJ and Wucherpfennig KW: Regulation
of T cell receptor activation by dynamic membrane binding of the
CD3epsilon cytoplasmic tyrosine-based motif. Cell. 135:702–713.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Isakov N, Wange RL, Burgess WH, Watts JD,
Aebersold R and Samelson LE: ZAP-70 binding specificity to T cell
receptor tyrosine-based activation motifs: The tandem SH2 domains
of ZAP-70 bind distinct tyrosine-based activation motifs with
varying affinity. J Exp Med. 181:375–380. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lo WL, Shah NH, Ahsan N, Horkova V,
Stepanek O, Salomon AR, Kuriyan J and Weiss A: Lck promotes
Zap70-dependent LAT phosphorylation by bridging Zap70 to LAT. Nat
Immunol. 19:733–741. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bubeck Wardenburg J, Fu C, Jackman JK,
Flotow H, Wilkinson SE, Williams DH, Johnson R, Kong G, Chan AC and
Findell PR: Phosphorylation of SLP-76 by the ZAP-70
protein-tyrosine kinase is required for T-cell receptor function. J
Biol Chem. 271:19641–19644. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wu L, Wei Q, Brzostek J and Gascoigne NRJ:
Signaling from T cell receptors (TCRs) and chimeric antigen
receptors (CARs) on T cells. Cell Mol Immunol. 17:600–612. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Courtney AH, Lo WL and Weiss A: TCR
signaling: Mechanisms of initiation and propagation. Trends Biochem
Sci. 43:108–123. 2018. View Article : Google Scholar
|
|
56
|
Ladygina N, Martin BR and Altman A:
Dynamic palmitoylation and the role of DHHC proteins in T cell
activation and anergy. Adv Immunol. 109:1–44. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Palacios EH and Weiss A: Function of the
Src-family kinases, Lck and Fyn, in T-cell development and
activation. Oncogene. 23:7990–8000. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
van Oers NS, Lowin-Kropf B, Finlay D,
Connolly K and Weiss A: alpha beta T cell development is abolished
in mice lacking both Lck and Fyn protein tyrosine kinases.
Immunity. 5:429–436. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Salmond RJ, Filby A, Qureshi I, Caserta S
and Zamoyska R: T-cell receptor proximal signaling via the
Src-family kinases, Lck and Fyn, influences T-cell activation,
differentiation, and tolerance. Immunol Rev. 228:9–22. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Webb Y, Hermida-Matsumoto L and Resh MD:
Inhibition of protein palmitoylation, raft localization, and T cell
signaling by 2-bromopalmitate and polyunsaturated fatty acids. J
Biol Chem. 275:261–270. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Resh MD: Fatty acylation of proteins: New
insights into membrane targeting of myristoylated and palmitoylated
proteins. Biochim Biophys Acta. 1451:1–16. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
van't Hof W and Resh MD: Rapid plasma
membrane anchoring of newly synthesized p59fyn: selective
requirement for NH2-terminal myristoylation and palmitoylation at
cysteine-3. J Cell Biol. 136:1023–1035. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Shenoy-Scaria AM, Dietzen DJ, Kwong J,
Link DC and Lublin DM: Cysteine3 of Src family protein tyrosine
kinase determines palmitoylation and localization in caveolae. J
Cell Biol. 126:353–363. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kosugi A, Hayashi F, Liddicoat DR, Yasuda
K, Saitoh S and Hamaoka T: A pivotal role of cysteine 3 of Lck
tyrosine kinase for localization to glycolipid-enriched
microdomains and T cell activation. Immunol Lett. 76:133–138. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Fan Y, Shayahati B, Tewari R, Boehning D
and Akimzhanov AM: Regulation of T cell receptor signaling by
protein acyltransferase DHHC21. Mol Biol Rep. 47:6471–6478. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
van't Hof W and Resh MD: Dual fatty
acylation of p59(Fyn) is required for association with the T cell
receptor zeta chain through phosphotyrosine-Src homology domain-2
interactions. J Cell Biol. 145:377–389. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
West SJ, Boehning D and Akimzhanov AM:
Regulation of T cell function by protein S-acylation. Front
Physiol. 13:10409682022. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Koegl M, Zlatkine P, Ley SC, Courtneidge
SA and Magee AI: Palmitoylation of multiple Src-family kinases at a
homologous N-terminal motif. Biochem J. 303(Pt 3): 749–753. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Das T, Yount JS and Hang HC: Protein
S-palmitoylation in immunity. Open Biol. 11:2004112021. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Au-Yeung BB, Shah NH, Shen L and Weiss A:
ZAP-70 in signaling, biology, and disease. Annu Rev Immunol.
36:127–156. 2018. View Article : Google Scholar
|
|
71
|
Smith-Garvin JE, Koretzky GA and Jordan
MS: T cell activation. Annu Rev Immunol. 27:591–619. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Paz PE, Wang S, Clarke H, Lu X, Stokoe D
and Abo A: Mapping the Zap-70 phosphorylation sites on LAT (linker
for activation of T cells) required for recruitment and activation
of signalling proteins in T cells. Biochem J. 356(Pt 2): 461–471.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Schultz A, Schnurra M, El-Bizri A,
Woessner NM, Hartmann S, Hartig R, Minguet S, Schraven B and
Simeoni L: A cysteine residue within the kinase domain of Zap70
regulates lck activity and proximal TCR signaling. Cells.
11:27232022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zhang W, Sloan-Lancaster J, Kitchen J,
Trible RP and Samelson LE: LAT: The ZAP-70 tyrosine kinase
substrate that links T cell receptor to cellular activation. Cell.
92:83–92. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Tewari R, Shayahati B, Fan Y and
Akimzhanov AM: T cell receptor-dependent S-acylation of ZAP-70
controls activation of T cells. J Biol Chem. 296:1003112021.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Hundt M, Harada Y, De Giorgio L, Tanimura
N, Zhang W and Altman A: Palmitoylation-dependent plasma membrane
transport but lipid raft-independent signaling by linker for
activation of T cells. J Immunol. 183:1685–1694. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zhang W, Irvin BJ, Trible RP, Abraham RT
and Samelson LE: Functional analysis of LAT in TCR-mediated
signaling pathways using a LAT-deficient Jurkat cell line. Int
Immunol. 11:943–950. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zhang W, Trible RP and Samelson LE: LAT
palmitoylation: Its essential role in membrane microdomain
targeting and tyrosine phosphorylation during T Cell Activation.
Immunity. 9:239–246. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Hundt M, Tabata H, Jeon MS, Hayashi K,
Tanaka Y, Krishna R, De Giorgio L, Liu YC, Fukata M and Altman A:
Impaired activation and localization of LAT in anergic T cells as a
consequence of a selective palmitoylation defect. Immunity.
24:513–522. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Tanimura N, Saitoh S, Kawano S, Kosugi A
and Miyake K: Palmitoylation of LAT contributes to its subcellular
localization and stability. Biochem Biophys Res Commun.
341:1177–1183. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Li Y, Yin Y and Mariuzza RA: Structural
and biophysical insights into the role of CD4 and CD8 in T cell
activation. Front Immunol. 4:2062013. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Baldwin I and Robey EA: Adjusting to self
in the thymus: CD4 versus CD8 lineage commitment and regulatory T
cell development. J Exp Med. 221:e202308962024. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Van Laethem F, Tikhonova AN and Singer A:
MHC restriction is imposed on a diverse T cell receptor repertoire
by CD4 and CD8 co-receptors during thymic selection. Trends
Immunol. 33:437–441. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Fragoso R, Ren D, Zhang X, Su MW, Burakoff
SJ and Jin YJ: Lipid raft distribution of CD4 depends on its
palmitoylation and association with Lck, and evidence for
CD4-induced lipid raft aggregation as an additional mechanism to
enhance CD3 signaling. J Immunol. 170:913–921. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Crise B and Rose JK: Identification of
palmitoylation sites on CD4, the human immunodeficiency virus
receptor. J Biol Chem. 267:13593–13597. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Lin H: Protein cysteine palmitoylation in
immunity and inflammation. FEBS J. 288:7043–7059. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Arcaro A, Grégoire C, Boucheron N, Stotz
S, Palmer E, Malissen B and Luescher IF: Essential role of CD8
palmitoylation in CD8 coreceptor function. J Immunol.
165:2068–2076. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Pang DJ, Hayday AC and Bijlmakers MJ: CD8
Raft localization is induced by its assembly into CD8alpha beta
heterodimers, Not CD8alpha alpha homodimers. J Biol Chem.
282:13884–13894. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Yang X, Chatterjee V, Ma Y, Zheng E and
Yuan SY: Protein palmitoylation in leukocyte signaling and
function. Front Cell Dev Biol. 8:6003682020. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Raychaudhuri K, Rangu R, Ma A, Alvinez N,
Tran AD, Pallikkuth S, McIntire KM, Garvey JA, Yi J and Samelson
LE: CD28 shapes T cell receptor signaling by regulating Lck
dynamics and ZAP70 activation. Front Immunol. 15:15030182024.
View Article : Google Scholar
|
|
91
|
Esensten JH, Helou YA, Chopra G, Weiss A
and Bluestone JA: CD28 costimulation: From mechanism to therapy.
Immunity. 44:973–988. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Lanier LL, O'Fallon S, Somoza C, Phillips
JH, Linsley PS, Okumura K, Ito D and Azuma M: CD80 (B7) and CD86
(B70) provide similar costimulatory signals for T cell
proliferation, cytokine production, and generation of CTL. J
Immunol. 154:97–105. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Sadra A, Cinek T and Imboden JB:
Translocation of CD28 to lipid rafts and costimulation of IL-2.
Proc Natl Acad Sci USA. 101:11422–11427. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Martin M, Schneider H, Azouz A and Rudd
CE: Cytotoxic T lymphocyte antigen 4 and CD28 modulate cell surface
raft expression in their regulation of T cell function. J Exp Med.
194:1675–1681. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Burke KP, Chaudhri A, Freeman GJ and
Sharpe AH: The B7:CD28 family and friends: Unraveling coinhibitory
interactions. Immunity. 57:223–244. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Slavik JM, Hutchcroft JE and Bierer BE:
CD28/CTLA-4 and CD80/CD86 families: Signaling and function. Immunol
Res. 19:1–24. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Lu B, Sun YY, Chen BY, Yang B, He QJ, Li J
and Cao J: zDHHC20-driven S-palmitoylation of CD80 is required for
its costimulatory function. Acta Pharmacol Sin. 45:1214–1223. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Simanshu DK, Nissley DV and McCormick F:
RAS proteins and their regulators in human disease. Cell.
170:17–33. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Lu S, Jang H, Muratcioglu S, Gursoy A,
Keskin O, Nussinov R and Zhang J: Ras conformational ensembles,
allostery, and signaling. Chem Rev. 116:6607–6665. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Kolch W, Berta D and Rosta E: Dynamic
regulation of RAS and RAS signaling. Biochem J. 480:1–23. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Downward J: Control of ras activation.
Cancer Surv. 27:87–100. 1996.PubMed/NCBI
|
|
102
|
Lapinski PE and King PD: Regulation of Ras
signal transduction during T cell development and activation. Am J
Clin Exp Immunol. 1:147–153. 2012.PubMed/NCBI
|
|
103
|
Kortum RL, Rouquette-Jazdanian AK and
Samelson LE: Ras and extracellular signal-regulated kinase
signaling in thymocytes and T cells. Trends Immunol. 34:259–268.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Yamashita M, Kimura M, Kubo M, Shimizu C,
Tada T, Perlmutter RM and Nakayama T: T cell antigen
receptor-mediated activation of the Ras/mitogen-activated protein
kinase pathway controls interleukin 4 receptor function and type-2
helper T cell differentiation. Proc Natl Acad Sci USA.
96:1024–1029. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Busquets-Hernández C and Triola G:
Palmitoylation as a key regulator of ras localization and function.
Front Mol Biosci. 8:6598612021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Castellano E and Santos E: Functional
specificity of ras isoforms: So similar but so different. Genes
Cancer. 2:216–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
García-España A and Philips MR: Origin and
evolution of RAS membrane targeting. Oncogene. 42:1741–1750. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Rocks O, Peyker A, Kahms M, Verveer PJ,
Koerner C, Lumbierres M, Kuhlmann J, Waldmann H, Wittinghofer A and
Bastiaens PI: An acylation cycle regulates localization and
activity of palmitoylated Ras isoforms. Science. 307:1746–1752.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Baekkeskov S and Kanaani J: Palmitoylation
cycles and regulation of protein function (Review). Mol Membr Biol.
26:42–54. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Oeckinghaus A and Ghosh S: The NF-kappaB
family of transcription factors and its regulation. Cold Spring
Harb Perspect Biol. 1:a0000342009. View Article : Google Scholar :
|
|
111
|
Mao H, Zhao X and Sun SC: NF-κB in
inflammation and cancer. Cell Mol Immunol. 22:811–839. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Lomaga MA, Yeh WC, Sarosi I, Duncan GS,
Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, et al:
TRAF6 deficiency results in osteopetrosis and defective
interleukin-1, CD40, and LPS signaling. Genes Dev. 13:1015–1024.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Liu E, Sun J, Yang J, Li L, Yang Q, Zeng
J, Zhang J, Chen D and Sun Q: ZDHHC11 positively regulates NF-κB
activation by enhancing TRAF6 oligomerization. Front Cell Dev Biol.
9:7109672021. View Article : Google Scholar
|
|
114
|
Feng T, Qin H, Wang L, Benveniste EN,
Elson CO and Cong Y: Th17 cells induce colitis and promote Th1 cell
responses through IL-17 induction of innate IL-12 and IL-23
production. J Immunol. 186:6313–6318. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Leppkes M, Becker C, Ivanov II, Hirth S,
Wirtz S, Neufert C, Pouly S, Murphy AJ, Valenzuela DM, Yancopoulos
GD, et al: RORgamma-expressing Th17 cells induce murine chronic
intestinal inflammation via redundant effects of IL-17A and IL-17F.
Gastroenterology. 136:257–267. 2009. View Article : Google Scholar
|
|
116
|
Zhang M, Zhou L, Xu Y, Yang M, Xu Y,
Komaniecki GP, Kosciuk T, Chen X, Lu X, Zou X, et al: A STAT3
palmitoylation cycle promotes T(H)17 differentiation and colitis.
Nature. 586:434–439. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Fujino S, Andoh A, Bamba S, Ogawa A, Hata
K, Araki Y, Bamba T and Fujiyama Y: Increased expression of
interleukin 17 in inflammatory bowel disease. Gut. 52:65–70. 2003.
View Article : Google Scholar
|
|
118
|
Kobayashi T, Okamoto S, Hisamatsu T,
Kamada N, Chinen H, Saito R, Kitazume MT, Nakazawa A, Sugita A,
Koganei K, et al: IL23 differentially regulates the Th1/Th17
balance in ulcerative colitis and Crohn's disease. Gut.
57:1682–1689. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Ahern PP, Schiering C, Buonocore S,
McGeachy MJ, Cua DJ, Maloy KJ and Powrie F: Interleukin-23 drives
intestinal inflammation through direct activity on T cells.
Immunity. 33:279–288. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Gagliani N, Amezcua Vesely MC, Iseppon A,
Brockmann L, Xu H, Palm NW, de Zoete MR, Licona-Limón P, Paiva RS,
Ching T, et al: Th17 cells transdifferentiate into regulatory T
cells during resolution of inflammation. Nature. 523:221–225. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Coskun M, Vermeire S and Nielsen OH: Novel
targeted therapies for inflammatory bowel disease. Trends Pharmacol
Sci. 38:127–142. 2017. View Article : Google Scholar
|
|
122
|
Zhou L, Zhang M, Wang Y, Dorfman RG, Liu
H, Yu T, Chen X, Tang D, Xu L, Yin Y, et al: Faecalibacterium
prausnitzii produces butyrate to maintain Th17/Treg balance and to
ameliorate colorectal colitis by inhibiting histone deacetylase 1.
Inflamm Bowel Dis. 24:1926–1940. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Yang XO, Panopoulos AD, Nurieva R, Chang
SH, Wang D, Watowich SS and Dong C: STAT3 regulates
cytokine-mediated generation of inflammatory helper T cells. J Biol
Chem. 282:9358–9363. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Saleh R and Elkord E: FoxP3+ T regulatory
cells in cancer: Prognostic biomarkers and therapeutic targets.
Cancer Lett. 490:174–185. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Takeuchi Y and Nishikawa H: Roles of
regulatory T cells in cancer immunity. Int Immunol. 28:401–409.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Li X and Zheng Y: Regulatory T cell
identity: Formation and maintenance. Trends Immunol. 36:344–353.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Riaz F, Huang Z and Pan F: Targeting
post-translational modifications of Foxp3: A new paradigm for
regulatory T cell-specific therapy. Front Immunol. 14:12807412023.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Deng G, Song X, Fujimoto S, Piccirillo CA,
Nagai Y and Greene MI: Foxp3 post-translational modifications and
treg suppressive activity. Front Immunol. 10:24862019. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Zhou B, Zhang M, Ma H, Wang Y, Qiu J, Liu
Y, Lu L, Li T, Zhang L, Huang R, et al: Distinct palmitoylation of
Foxp3 regulates the function of regulatory T cells via
palmitoyltransferases. Cell Mol Immunol. 21:787–789. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Lee TA, Tsai EY, Liu SH, Hsu Hung SD,
Chang SJ, Chao CH, Lai YJ, Yamaguchi H and Li CW:
Post-translational modification of PD-1: Potential targets for
cancer immunotherapy. Cancer Res. 84:800–807. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Ostrand-Rosenberg S, Horn LA and Haile ST:
The programmed death-1 immune-suppressive pathway: Barrier to
antitumor immunity. J Immunol. 193:3835–3841. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Zhang Z, Ren C, Xiao R, Ma S, Liu H, Dou
Y, Fan Y, Wang S, Zhan P, Gao C, et al: Palmitoylation of TIM-3
promotes immune exhaustion and restrains antitumor immunity. Sci
Immunol. 9:eadp73022024. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Riley JL: PD-1 signaling in primary T
cells. Immunol Rev. 229:114–125. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Chemnitz JM, Parry RV, Nichols KE, June CH
and Riley JL: SHP-1 and SHP-2 associate with immunoreceptor
tyrosine-based switch motif of programmed death 1 upon primary
human T cell stimulation, but only receptor ligation prevents T
cell activation. J Immunol. 173:945–954. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Yao H, Li C, He F, Song T, Brosseau JP,
Wang H, Lu H, Fang C, Shi H, Lan J, et al: A peptidic inhibitor for
PD-1 palmitoylation targets its expression and functions. RSC Chem
Biol. 2:192–205. 2020. View Article : Google Scholar
|
|
136
|
Zhu C, Anderson AC, Schubart A, Xiong H,
Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3
ligand galectin-9 negatively regulates T helper type 1 immunity.
Nat Immunol. 6:1245–1252. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
137
|
Zhao L, Cheng S, Fan L, Zhang B and Xu S:
TIM-3: An update on immunotherapy. Int Immunopharmacol.
99:1079332021. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Das M, Zhu C and Kuchroo VK: Tim-3 and its
role in regulating anti-tumor immunity. Immunol Rev. 276:97–111.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Wolf Y, Anderson AC and Kuchroo VK: TIM3
comes of age as an inhibitory receptor. Nat Rev Immunol.
20:173–185. 2020. View Article : Google Scholar :
|
|
140
|
Tiegs G and Horst AK: TNF in the liver:
Targeting a central player in inflammation. Semin Immunopathol.
44:445–459. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Kalliolias GD and Ivashkiv LB: TNF
biology, pathogenic mechanisms and emerging therapeutic strategies.
Nat Rev Rheumatol. 12:49–62. 2016. View Article : Google Scholar :
|
|
142
|
Gough P and Myles IA: Tumor necrosis
factor receptors: Pleiotropic signaling complexes and their
differential effects. Front Immunol. 11:5858802020. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Tartaglia LA, Ayres TM, Wong GH and
Goeddel DV: A novel domain within the 55 kd TNF receptor signals
cell death. Cell. 74:845–853. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Jang DI, Lee AH, Shin HY, Song HR, Park
JH, Kang TB, Lee SR and Yang SH: The role of tumor necrosis factor
alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in
therapeutics. Int J Mol Sci. 22:27192021. View Article : Google Scholar
|
|
145
|
Zingler P, Särchen V, Glatter T, Caning L,
Saggau C, Kathayat RS, Dickinson BC, Adam D, Schneider-Brachert W,
Schütze S and Fritsch J: Palmitoylation is required for TNF-R1
signaling. Cell Commun Signal. 17:902019. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Micheau O and Tschopp J: Induction of TNF
receptor I-mediated apoptosis via two sequential signaling
complexes. Cell. 114:181–190. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Schneider-Brachert W, Tchikov V, Neumeyer
J, Jakob M, Winoto-Morbach S, Held-Feindt J, Heinrich M, Merkel O,
Ehrenschwender M, Adam D, et al: Compartmentalization of TNF
receptor 1 signaling: Internalized TNF receptosomes as death
signaling vesicles. Immunity. 21:415–428. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Cruz AC, Ramaswamy M, Ouyang C, Klebanoff
CA, Sengupta P, Yamamoto TN, Meylan F, Thomas SK, Richoz N, Eil R,
et al: Fas/CD95 prevents autoimmunity independently of lipid raft
localization and efficient apoptosis induction. Nat Commun.
7:138952016. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Krueger A, Schmitz I, Baumann S, Krammer
PH and Kirchhoff S: Cellular FLICE-inhibitory protein splice
variants inhibit different steps of caspase-8 activation at the
CD95 death-inducing signaling complex. J Biol Chem.
276:20633–20640. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Kischkel FC, Hellbardt S, Behrmann I,
Germer M, Pawlita M, Krammer PH and Peter ME:
Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a
death-inducing signaling complex (DISC) with the receptor. EMBO J.
14:5579–5588. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Chakrabandhu K, Hérincs Z, Huault S, Dost
B, Peng L, Conchonaud F, Marguet D, He HT and Hueber AO:
Palmitoylation is required for efficient Fas cell death signaling.
EMBO J. 26:209–220. 2007. View Article : Google Scholar
|
|
152
|
Feig C, Tchikov V, Schütze S and Peter ME:
Palmitoylation of CD95 facilitates formation of SDS-stable receptor
aggregates that initiate apoptosis signaling. EMBO J. 26:221–231.
2007. View Article : Google Scholar
|
|
153
|
Rossin A, Durivault J, Chakhtoura-Feghali
T, Lounnas N, Gagnoux-Palacios L and Hueber AO: Fas palmitoylation
by the palmitoyl acyltransferase DHHC7 regulates Fas stability.
Cell Death Differ. 22:643–653. 2015. View Article : Google Scholar
|
|
154
|
Hueber AO, Bernard AM, Hérincs Z, Couzinet
A and He HT: An essential role for membrane rafts in the initiation
of Fas/CD95-triggered cell death in mouse thymocytes. EMBO Rep.
3:190–196. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Janssen O, Qian J, Linkermann A and
Kabelitz D: CD95 ligand-death factor and costimulatory molecule?
Cell Death Differ. 10:1215–1225. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Guardiola-Serrano F, Rossin A, Cahuzac N,
Lückerath K, Melzer I, Mailfert S, Marguet D, Zörnig M and Hueber
AO: Palmitoylation of human FasL modulates its cell death-inducing
function. Cell Death Dis. 1:e882010. View Article : Google Scholar
|
|
157
|
Rao Z, Huang C, Wu Q, Li M, Liu A, Zhu T,
Yang W, Yin L, Zhu S, She X, et al: Palmitic acid-triggered B7H3
palmitoylation promotes immune escape. Nat Commun. 17:18102026.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Sun Y, Tang W, Xia Y, Xia M, Liu G, Zhang
W, Chen Y and Zhong J: Bridging metabolic reprogramming and
targeted therapy: the critical role of S-palmitoylation in cancer.
Front Cell Dev Biol. 14:18021092026. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Yan Y, Yu J, Wang W, Xu Y, Tison K, Xiao
R, Grove S, Wei S, Vatan L, Wicha M, et al: Palmitoylation prevents
B7-H4 lysosomal degradation sustaining tumor immune evasion. Nat
Commun. 16:42542025. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Du W, Hua F, Li X, Zhang J, Li S, Wang W,
Zhou J, Wang W, Liao P, Yan Y, et al: Loss of optineurin drives
cancer immune evasion via palmitoylation-dependent IFNGR1 lysosomal
sorting and degradation. Cancer Discov. 11:1826–1843. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Jiang X, Wang J, Deng X, Xiong F, Ge J,
Xiang B, Wu X, Ma J, Zhou M, Li X, et al: Zeng, Role of the tumor
microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol
Cancer. 18:102019. View Article : Google Scholar
|
|
162
|
Sun C, Mezzadra R and Schumacher TN:
Regulation and function of the PD-L1 checkpoint. Immunity.
48:434–452. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Wang Q, Wang J, Yu D, Zhang Q, Hu H, Xu M,
Zhang H, Tian S, Zheng G, Lu D, et al: Benzosceptrin C induces
lysosomal degradation of PD-L1 and promotes antitumor immunity by
targeting DHHC3. Cell Rep Med. 5:1013572024. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Azuma T, Yao S, Zhu G, Flies AS, Flies SJ
and Chen L: B7-H1 is a ubiquitous antiapoptotic receptor on cancer
cells. Blood. 111:3635–3643. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Yang Y, Hsu JM, Sun L, Chan LC, Li CW, Hsu
JL, Wei Y, Xia W, Hou J, Qiu Y and Hung MC: Palmitoylation
stabilizes PD-L1 to promote breast tumor growth. Cell Res.
29:83–86. 2019. View Article : Google Scholar
|
|
166
|
Yao H, Lan J, Li C, Shi H, Brosseau JP,
Wang H, Lu H, Fang C, Zhang Y, Liang L, et al: Inhibiting PD-L1
palmitoylation enhances T-cell immune responses against tumours.
Nat Biomed Eng. 3:306–317. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Huang Y, Zhang HL, Li ZL, Du T, Chen YH,
Wang Y, Ni HH, Zhang KM, Mai J, Hu BX, et al: FUT8-mediated
aberrant N-glycosylation of B7H3 suppresses the immune response in
triple-negative breast cancer. Nat Commun. 12:26722021. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Huang Y, Zhong WQ, Yang XY, Shan JL, Zhou
L, Li ZL, Guo YQ, Zhang KM, Du T, Zhang HL, et al: Targeting
site-specific N-glycosylated B7H3 induces potent antitumor
immunity. Nat Commun. 16:35462025. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Ma Y, Yang Y, Huang Y, Fang W, Xue J, Meng
X, Fan Y, Fu S, Wu L, Zheng Y, et al: A B7H3-targeting
antibody-drug conjugate in advanced solid tumors: A phase 1/1b
trial. Nat Med. 31:1949–1957. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Agarwal S, Fang L, McGowen K, Yin J,
Bowman J, Ku AT, Alilin AN, Corey E, Roudier MP, True LD, et al:
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug
conjugate treatment in metastatic prostate cancer models. J Clin
Invest. 133:e1621482023. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Lee YH, Martin-Orozco N, Zheng P, Li J,
Zhang P, Tan H, Park HJ, Jeong M, Chang SH, Kim BS, et al:
Inhibition of the B7-H3 immune checkpoint limits tumor growth by
enhancing cytotoxic lymphocyte function. Cell Res. 27:1034–1045.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Yonesaka K, Haratani K, Takamura S, Sakai
H, Kato R, Takegawa N, Takahama T, Tanaka K, Hayashi H, Takeda M,
et al: B7-H3 negatively modulates CTL-mediated cancer immunity.
Clin Cancer Res. 24:2653–2664. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Prasad DV, Richards S, Mai XM and Dong C:
B7S1, a novel B7 family member that negatively regulates T cell
activation. Immunity. 18:863–873. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Zang X, Loke P, Kim J, Murphy K, Waitz R
and Allison JP: B7x: A widely expressed B7 family member that
inhibits T cell activation. Proc Natl Acad Sci USA.
100:10388–10392. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Sica GL, Choi IH, Zhu G, Tamada K, Wang
SD, Tamura H, Chapoval AI, Flies DB, Bajorath J and Chen L: B7-H4,
a molecule of the B7 family, negatively regulates T cell immunity.
Immunity. 18:849–861. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Smith JB, Stashwick C and Powell DJ: B7-H4
as a potential target for immunotherapy for gynecologic cancers: A
closer look. Gynecol Oncol. 134:181–189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
MacGregor HL and Ohashi PS: Molecular
pathways: Evaluating the potential for B7-H4 as an immunoregulatory
target. Clin Cancer Res. 23:2934–2941. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Siegel RL, Miller KD, Goding Sauer A,
Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal
A: Colorectal cancer statistics, 2020. CA Cancer J Clin.
70:145–164. 2020.PubMed/NCBI
|
|
179
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Boland CR and Goel A: Microsatellite
instability in colorectal cancer. Gastroenterology.
138:2073–2087.e3. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Du W, Frankel TL, Green M and Zou W: IFNγ
signaling integrity in colorectal cancer immunity and
immunotherapy. Cell Mol Immunol. 19:23–32. 2022. View Article : Google Scholar :
|
|
182
|
Castro F, Cardoso AP, Gonçalves RM, Serre
K and Oliveira MJ: Interferon-Gamma at the crossroads of tumor
immune surveillance or evasion. Front Immunol. 9:8472018.
View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Galati D and Zanotta S: Dendritic cell and
cancer therapy. Int J Mol Sci. 24:42532023. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Merad M, Sathe P, Helft J, Miller J and
Mortha A: The dendritic cell lineage: Ontogeny and function of
dendritic cells and their subsets in the steady state and the
inflamed setting. Annu Rev Immunol. 31:563–604. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Chesarino NM, Hach JC, Chen JL, Zaro BW,
Rajaram MV, Turner J, Schlesinger LS, Pratt MR, Hang HC and Yount
JS: Chemoproteomics reveals Toll-like receptor fatty acylation. BMC
Biol. 12:912014. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Quiroz JN, Sielaff M, Kondrateva D,
Boukhallouk F, Godoy GJ, Molina CR, Moonen B, Motran CC, Bogie J,
Luján HD, et al: TLR9-Driven S-Palmitoylation in dendritic cells
reveals immune and metabolic protein targets. Eur J Immunol.
55:e700392025. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Ni H, Wang Y, Yao K, Wang L, Huang J, Xiao
Y, Chen H, Liu B, Yang CY and Zhao J: Cyclical palmitoylation
regulates TLR9 signalling and systemic autoimmunity in mice. Nat
Commun. 15:12024. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Stolk DA, Horrevorts SK, Schetters STT,
Kruijssen LJW, Duinkerken S, Keuning E, Ambrosini M, Kalay H, van
de Ven R, Garcia-Vallejo JJ, et al: Palmitoylated antigens for the
induction of anti-tumor CD8+ T cells and enhanced tumor
recognition. Mol Ther Oncolytics. 21:315–328. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Bian X, Liu R, Meng Y, Xing D, Xu D and Lu
Z: Lipid metabolism and cancer. J Exp Med. 218:e202016062021.
View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Xu M and Xu B: Protein lipidation in the
tumor microenvironment: Enzymology, signaling pathways, and
therapeutics. Mol Cancer. 24:1382025. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Wang J, Hao JW, Wang X, Guo H, Sun HH, Lai
XY, Liu LY, Zhu M, Wang HY, Li YF, et al: DHHC4 and DHHC5
facilitate fatty acid uptake by palmitoylating and targeting CD36
to the plasma membrane. Cell Rep. 26:209–221.e5. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Fhu CW and Ali A: Protein lipidation by
palmitoylation and myristoylation in cancer. Front Cell Dev Biol.
9:6736472021. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Dennis KMJH and Heather LC:
Post-translational palmitoylation of metabolic proteins. Front
Physiol. 14:11228952023. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Hao JW, Wang J, Guo H, Zhao YY, Sun HH, Li
YF, Lai XY, Zhao N, Wang X, Xie C, et al: CD36 facilitates fatty
acid uptake by dynamic palmitoylation-regulated endocytosis. Nat
Commun. 11:47652020. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Mo Y, Han Y, Chen Y, Fu C, Li Q, Liu Z,
Xiao M and Xu B: ZDHHC20 mediated S-palmitoylation of fatty acid
synthase (FASN) promotes hepatocarcinogenesis. Mol Cancer.
23:2742024. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Jennings BC, Nadolski MJ, Ling Y, Baker
MB, Harrison ML, Deschenes RJ and Linder ME: 2-Bromopalmitate and
2-(2-hydr oxy-5-nitro-benzylidene)-benzo[b]thiophen-3-one inhibit
DHHC-mediated palmitoylation in vitro. J Lipid Res. 50:233–242.
2009. View Article : Google Scholar
|
|
197
|
Liu Y, Hu S, Önder O, Sahasrabuddhe A,
Rajabi A, Seitz A, de Jong D, Koerts J, Visser L,
Dzikiewicz-Krawczyk A, et al: Palmitoylation by ZDHHC family
members regulate B-cell lymphoma growth. Int J Biol Macromol.
320(Pt 2): 1458762025. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Tang F, Yang C, Li FP, Yu DH, Pan ZY, Wang
ZF and Li ZQ: Palmitoyl transferases act as potential regulators of
tumor-infiltrating immune cells and glioma progression. Mol Ther
Nucleic Acids. 28:716–731. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Shi X, Zhao X, He Y, Zhang L, Zheng X, Qin
X, Li K, Li J, Wang Y, Dai L and Li X: Posttranslational remodeling
micelle reverses cell-surface and exosomal PD-L1 immunosuppression
in tumors resistant to PD-L1 antibody therapy. J Control Release.
384:1139612025. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Yuan Y, Wang MR, Ding Y, Lin Y, Xu TT, He
XX and Li PY: Lenvatinib promotes hepatocellular carcinoma
pyroptosis by regulating GSDME palmitoylation. Cancer Biol Ther.
26:25322172025. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Davda D, El Azzouny MA, Tom CT, Hernandez
JL, Majmudar JD, Kennedy RT and Martin BR: Profiling targets of the
irreversible palmitoylation inhibitor 2-bromopalmitate. ACS Chem
Biol. 8:1912–1927. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Zhang G, Jiang P, Tang W, Wang Y, Qiu F,
An J, Zheng Y, Wu D, Zhou J, Neculai D, et al: CPT1A induction
following epigenetic perturbation promotes MAVS palmitoylation and
activation to potentiate antitumor immunity. Mol Cell.
83:4370–4385.e9. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Zhou L, Lian G, Zhou T, Cai Z, Yang S, Li
W, Cheng L, Ye Y, He M, Lu J, et al: Palmitoylation of GPX4 via the
targetable ZDHHC8 determines ferroptosis sensitivity and antitumor
immunity. Nat Cancer. 6:768–785. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Zhang X, Liao X, Wang M, Liu J, Han J, An
D, Zheng T, Wang X, Cheng H and Liu P: Inhibition of
palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to
cisplatin through ROS-mediated mechanisms. Cancer Sci.
115:1170–1183. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Shao S, Li W, Hong Y, Zeng R, Zhu L, Yi L,
Li Y, Wang Y, Huang H, Jiang X and Jin X: ZDHHC2-Dependent
palmitoylation dictates ferroptosis and castration sensitivity in
prostate cancer via controlling ACSL4 Degradation and lipid
peroxidation. Adv Sci (Weinh). 13:e140772026. View Article : Google Scholar :
|
|
206
|
Shahid M, Kim M, Jin P, Zhou B, Wang Y,
Yang W, You S and Kim J: S-Palmitoylation as a functional regulator
of proteins associated with cisplatin resistance in bladder cancer.
Int J Biol Sci. 16:2490–2505. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Rana MS, Kumar P, Lee CJ, Verardi R,
Rajashankar KR and Banerjee A: Fatty acyl recognition and transfer
by an integral membrane S-acyltransferase. Science.
359:eaao63262018. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Wong DY, Ong WW and Ang WH: Induction of
immunogenic cell death by chemotherapeutic platinum complexes.
Angew Chem Int Ed Engl. 54:6483–6487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Chang X, Bian B, Liu L, Yang J, Yang Z,
Wang Z, Lu Y and Liu W: Induction of immunogenic cell death by
novel platinum-based anticancer agents. Pharmacol Res.
187:1065562023. View Article : Google Scholar
|
|
210
|
Martins I, Kepp O, Schlemmer F, Adjemian
S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N,
et al: Restoration of the immunogenicity of cisplatin-induced
cancer cell death by endoplasmic reticulum stress. Oncogene.
30:1147–1158. 2011. View Article : Google Scholar
|
|
211
|
Guo Y, Wang X, Zhang C, Chen W, Fu Y, Yu
Y, Chen Y, Shao T, Zhang J and Ding G: Tumor Immunotherapy
targeting B7-H3: From mechanisms to clinical applications.
Immunotargets Ther. 14:291–320. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Picarda E, Ohaegbulam KC and Zang X:
Molecular pathways: Targeting B7-H3 (CD276) for human cancer
immunotherapy. Clin Cancer Res. 22:3425–3431. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Cuyàs E, Pedarra S, Verdura S, Pardo MA,
Espin Garcia R, Serrano-Hervás E, Llop-Hernández A, Teixidor E,
Bosch-Barrera J, López-Bonet E, et al: Fatty acid synthase (FASN)
is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell
immunity. Cell Death Discov. 10:4172024. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Qian YR, Zhao YJ and Zhang F: Protein
palmitoylation: Biological functions, disease, and therapeutic
targets. MedComm (2020). 6:e700962025. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Lan T, Delalande C and Dickinson BC:
Inhibitors of DHHC family proteins. Curr Opin Chem Biol.
65:118–125. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Li Z, Jiang D, Liu F and Li Y: Involvement
of ZDHHC9 in lung adenocarcinoma: Regulation of PD-L1 stability via
palmitoylation. In Vitro Cell Dev Biol Anim. 59:193–203. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Lin Z, Huang K, Guo H, Jia M, Sun Q, Chen
X, Wu J, Yao Q, Zhang P, Vakal S, et al: Targeting ZDHHC9
potentiates anti-programmed death-ligand 1 immunotherapy of
pancreatic cancer by modifying the tumor microenvironment. Biomed
Pharmacother. 161:1145672023. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Li Y, Xiang S, Pan W, Wang J, Zhan H and
Liu S: Targeting tumor immunosuppressive microenvironment for
pancreatic cancer immunotherapy: Current research and future
perspective. Front Oncol. 13:11668602023. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Lin Z, Lv Z, Liu X and Huang K: Palmitoyl
transferases act as novel drug targets for pancreatic cancer. J
Transl Med. 21:2492023. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Zhou D, Wu Z, Cui Y, Wang D, Song H, Chen
J and Lin H: Systematic analysis of ZDHHC9 as a potential
prognostic and immunotherapy biomarker in breast cancer. Front
Immunol. 16:16096212025. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Xiao Q, Bu J, Liu M, Shi L and Qu C:
Acylation modification mediated post-translational modifications
learning signature reveals ZDHHC18 promotes progression of lung
adenocarcinoma by attenuating immunocyte activation. Front Immunol.
17:18026312026. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Lu C, He Y, Zhang LQ, Miao JY and Wang W:
zDHHC-mediated palmitoylation modification patterns and tumor
immune microenvironment infiltration characterization in pancreatic
cancer. Int Immunopharmacol. 168(Pt 2): 1158632026. View Article : Google Scholar
|
|
223
|
Zhu H, Hu H, Hao B, Zhan W, Yan T, Zhang
J, Wang S, Hu H and Zhang T: Insights into a machine learning-based
palmitoylation-related gene model for predicting the prognosis and
treatment response of breast cancer patients. Technol Cancer Res
Treat. 23:153303382412634342024. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Zeng S, Zeng L, Xie X and Peng L:
Palmitoylation-related gene expression and its prognostic value in
ovarian cancer: Insights into immune infiltration and therapeutic
potential. Discov Oncol. 15:8022024. View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Wang X, Li J, Wang Z and Wu Q:
Comprehensive analysis of a palmitoylation-related prognostic
signature in colorectal cancer: Implications for immune therapy and
personalized treatment. Oncol Lett. 30:3502025.PubMed/NCBI
|
|
226
|
Pedro MP, Vilcaes AA, Tomatis VM, Oliveira
RG, Gomez GA and Daniotti JL: 2-Bromopalmitate reduces protein
deacylation by inhibition of acyl-protein thioesterase enzymatic
activities. PLoS One. 8:e752322013. View Article : Google Scholar : PubMed/NCBI
|
